The Effect of Pregabalin on the Minimum Alveolar Concentration of Sevoflurane: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial.

Front Med (Lausanne)

Division of General Anaesthesia and Intensive Care Medicine, Department of Anaesthesia, Intensive Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.

Published: May 2022

Background: Pregabalin is commonly used perioperatively to reduce post-operative pain and opioid consumption and to prevent the development of chronic pain. It has been shown to reduce anesthetic consumption in balanced anesthesia, but studies investigating its effect on the minimum alveolar concentration (MAC) of volatile anesthetics are lacking. The aim of this study was to investigate the effect of two different doses of pregabalin on the MAC of sevoflurane.

Methods: In a randomized, double-blinded, placebo controlled clinical study, 75 patients were assigned to receive placebo, 300 mg pregabalin, or 150 mg pregabalin, as a capsule 1 h before anesthesia induction with sevoflurane only. After equilibration, the response to skin incision (movement vs. non-movement) was monitored. The MAC was assessed using an up- and down-titration method.

Results: The MAC of sevoflurane was estimated as 2.16% (95% CI, 2.07-2.32%) in the placebo group, 1.44% (95% CI, 1.26-1.70%) in the 300 mg pregabalin group, and 1.81% (95% CI, 1.49-2.13%) in the 150 mg pregabalin group. We therefore report a 33% reduction in the MAC of sevoflurane in the 300 mg pregabalin group as compared to placebo. The MAC of the 150 mg pregabalin group was reduced by 16% as compared to placebo but was not statistically significant.

Conclusions: The administration of 300 mg pregabalin reduced the MAC of sevoflurane by 33%, while the administration of 150 mg pregabalin did not significantly reduce the MAC of sevoflurane. Pregabalin use led to a small reduction in post-operative pain levels but increased side effects in a dose-dependent manner.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110662PMC
http://dx.doi.org/10.3389/fmed.2022.883181DOI Listing

Publication Analysis

Top Keywords

300 pregabalin
16
150 pregabalin
16
mac sevoflurane
16
pregabalin group
16
pregabalin
12
minimum alveolar
8
alveolar concentration
8
post-operative pain
8
mac
8
compared placebo
8

Similar Publications

Introduction: Despite the emergence of drugs to treat irritable bowel syndrome (IBS), improving abdominal pain can still be challenging. αδ ligands, such as gabapentin and pregabalin, are sometimes used off-label to tackle this problem. However, evidence for efficacy is limited, and no large-scale studies have been published.

View Article and Find Full Text PDF

The effects of gabapentin and pregabalin on fracture healing: A histological, radiological, and biomechanical analysis.

Jt Dis Relat Surg

January 2025

Balıkesir Üniversitesi Tıp Fakültesi Ortopedi ve Travmatoloji Anabilim Dalı, 10185 Altıeylül, Balıkesir, Türkiye.

Objectives: This study evaluated the impact of different doses of gabapentin and pregabalin on fracture healing in a rat femoral shaft model, with histological, radiological, and biomechanical assessments.

Materials And Methods: Seventy male Wistar albino rats were divided into five groups: control, low-dose gabapentin (GBP-L, 300 mg/day), high-dose gabapentin (GBP-H, 3600 mg/day), low-dose pregabalin (PRG-L, 150 mg/day), and high-dose pregabalin (PRG-H, 600 mg/day), based on human equivalent doses. Bilateral femoral fractures were induced; the right femurs were prepared for radiological examination using microtomography, followed by histological analysis, whereas the left femurs were allocated for biomechanical testing.

View Article and Find Full Text PDF

Background: Behavioral and Psychological Symptoms of Dementia (BPSD) are common during Alzheimer's disease and cause severe problems for patients and their caregivers.

Objectives: To assess the therapeutic efficacy of Pregabalin in comparison with a placebo in treating BPSD in patients with Alzheimer's disease (AD) visiting the memory and cognition clinic of Roozbeh Psychiatric Hospital in Tehran, Iran.

Methods: A 12-week double-blind, randomized comparison of Pregabalin and placebo treatments was conducted in 53 patients with DSM-V diagnosis of dementia of Alzheimer's type.

View Article and Find Full Text PDF

Background: Diabetic peripheral neuropathy (DPN) is a chronic microvascular complication in diabetic mellitus patients due to chronic hyperglycemia, resulting in platelet hyperactivity and dyslipidemia. Alpha-lipoic acid (ALA) is a potent antioxidant which has antiplatelet activity and lipid-modulating characteristics and plays a major role in the prevention of disease progression.

Aim: To evaluate the effect of ALA on inhibition of platelet aggregation and lipid profile.

View Article and Find Full Text PDF

Introduction: Head and neck cancer (HNC) patients may experience neuropathic pain (NP) due to radiotherapy (RT), which may become chronic. Pregabalin, an anticonvulsant, alters the transmission of painful stimuli at the synaptic level, modifying their perception. Pregabalin is used in NP treatment, but limited data exist on RT-treated HNC patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!